Evernorth's Bio-Pharmaceutical Advancements
Evernorth Health Services is making waves in the pharmaceutical industry with its announcement to launch a biosimilar to Stelara, offering it at an incredible $0 out-of-pocket cost for eligible Accredo patients. This initiative is set to debut early next year and reflects a strong commitment to making essential medications more affordable for those who need them most.
Significant Savings for Patients
This innovative biosimilar is projected to save individual patients around $4,000 each year, significantly increasing access to life-changing treatments. Priced over 80% lower than the current Stelara list price, it presents a financially viable option for many. This groundbreaking strategy is especially advantageous for employers and health plan sponsors who are looking to mitigate healthcare costs.
Comprehensive Patient Support
Leading this transformation is Accredo, Evernorth's specialty pharmacy, known for its exceptional clinical support. Currently, more than 30,000 Accredo patients are using Stelara, and specialty-trained pharmacists and nurses are on hand 24/7 to help patients manage their treatment plans. Accredo's Therapeutic Resource Centers provide personalized resources, ensuring that patients receive the highest quality of care tailored to their specific needs.
Building a Future of Affordability
Matt Perlberg, president of Evernorth's pharmacy and care delivery businesses, shared insights into the vision driving this initiative. By harnessing advanced supply chain capabilities and clinical expertise, Evernorth is well-positioned to significantly enhance the affordability and accessibility of essential treatments. This announcement follows the successful launch of an interchangeable Humira biosimilar, underscoring Evernorth's proactive approach in the ever-evolving pharmaceutical landscape.
Bio-Pharmaceutical Strategy
Evernorth’s strategy not only focuses on introducing cost-effective biosimilars but also emphasizes improving patient outcomes through accessible care. The blend of innovative products and dedicated clinical support demonstrates a comprehensive approach aimed at benefiting individual patients while addressing wider healthcare costs.
About Evernorth Health Services
Evernorth Health Services is dedicated to enhancing health and vitality through innovative pharmacy, care, and benefits solutions. The company aims to make illness prediction and prevention more accessible, ultimately improving the quality of life for millions. With a range of services backed by established entities like Express Scripts and Accredo, Evernorth is at the forefront of transforming healthcare accessibility.
Frequently Asked Questions
What is the benefit of the Stelara biosimilar announced by Evernorth?
The Stelara biosimilar is expected to save patients around $4,000 per year, making essential treatments more affordable.
How does the copay assistance work for patients?
Eligible patients will have their out-of-pocket costs reduced to $0 through Quallent's copay assistance program.
Who will provide support to patients using the Stelara biosimilar?
Accredo provides top-tier clinical support through specialty-trained pharmacists and nurses, available 24/7.
What other biosimilars does Evernorth offer?
Evernorth has successfully launched an interchangeable Humira biosimilar, enhancing affordability for patients in need.
Which company owns Evernorth Health Services?
Evernorth Health Services is a wholly-owned subsidiary of The Cigna Group, enhancing its healthcare offerings.
